Rethinking the management of immune checkpoint inhibitor‐related adrenal insufficiency in cancer patients during the COVID‐19 pandemic

Abstract

The coronavirus disease 2019 (COVID‐19) is currently a major pandemic challenge, and cancer patients are at a heightened risk of severity and mortality from this infection. In recent years, immune checkpoint inhibitor (ICI) use to treat multiple cancers has increased in oncology, but equally has raised the question of whether ICI therapy and its side‐effects is harmful or beneficial during this pandemic.